JP2009539362A - Ｇタンパク質共役型受容体３９（ｇｐｒ３９） - Google Patents

Ｇタンパク質共役型受容体３９（ｇｐｒ３９） Download PDF

Info

Publication number
JP2009539362A
JP2009539362A JP2009513702A JP2009513702A JP2009539362A JP 2009539362 A JP2009539362 A JP 2009539362A JP 2009513702 A JP2009513702 A JP 2009513702A JP 2009513702 A JP2009513702 A JP 2009513702A JP 2009539362 A JP2009539362 A JP 2009539362A
Authority
JP
Japan
Prior art keywords
gpr39
seq
compound
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009513702A
Other languages
English (en)
Japanese (ja)
Inventor
モレオ，ベノワ・クリステイアン・ジヤン−クロード
モーシヤール，デイーデリク・ウイレム・エリザベト
ベル・ドンク，リユク・オグスト・ローレンテイウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2009539362A publication Critical patent/JP2009539362A/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009513702A 2006-06-08 2007-06-08 Ｇタンパク質共役型受容体３９（ｇｐｒ３９） Ceased JP2009539362A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06115158 2006-06-08
PCT/EP2007/055636 WO2007141322A1 (fr) 2006-06-08 2007-06-08 Récepteur couplé à la protéine g 39 (gpr39)

Publications (1)

Publication Number Publication Date
JP2009539362A true JP2009539362A (ja) 2009-11-19

Family

ID=37198919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009513702A Ceased JP2009539362A (ja) 2006-06-08 2007-06-08 Ｇタンパク質共役型受容体３９（ｇｐｒ３９）

Country Status (6)

Country Link
EP (1) EP2030024A1 (fr)
JP (1) JP2009539362A (fr)
CN (1) CN101467047A (fr)
CA (1) CA2652398A1 (fr)
MX (1) MX2008015670A (fr)
WO (1) WO2007141322A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4070797A4 (fr) * 2019-11-01 2023-11-29 Peking University Utilisation d'acides biliaires et de dérivés de ceux-ci dans la préparation d'un agoniste gpr39
US20230174484A1 (en) 2020-04-30 2023-06-08 Oregon Health & Science University Antagonists of gpr39 protein
KR20240093844A (ko) 2021-10-26 2024-06-24 바소카데아, 인코포레이티드 Gpr39 단백질의 길항제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081634A2 (fr) * 2000-04-26 2001-11-01 Millennium Pharmaceuticals, Inc. Methodes et compositions destinees au diagnostic et au traitement des maladies cardio-vasculaires et tumorigenes a l'aide de 4941
US20030232769A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 39 expression
US20040071708A1 (en) * 2002-09-26 2004-04-15 Immusol, Inc. GPR 39 modulators that control cancerous cell growth
WO2004039837A2 (fr) * 2002-10-31 2004-05-13 Janssen Pharmaceutica N.V. Genes reagissant a l'hormone liberatrice de la corticotropine dans le systeme nerveux central
WO2004097411A1 (fr) * 2003-04-25 2004-11-11 Takeda Pharmaceutical Company Limited Nouvelle methode de criblage
EP1623230A2 (fr) * 2003-05-05 2006-02-08 Bayer HealthCare AG Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
CN101107529A (zh) * 2004-12-01 2008-01-16 詹森药业有限公司 G蛋白偶联受体

Also Published As

Publication number Publication date
WO2007141322A1 (fr) 2007-12-13
EP2030024A1 (fr) 2009-03-04
CN101467047A (zh) 2009-06-24
MX2008015670A (es) 2009-01-12
CA2652398A1 (fr) 2007-12-13

Similar Documents

Publication Publication Date Title
JP2006523440A (ja) 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法
EP1377834A2 (fr) Medicaments modulateurs de hm74 et/ou de l'activite de hm74a
US20100168014A1 (en) Screening method
JPH11169187A (ja) 新規化合物
JP2009539362A (ja) Ｇタンパク質共役型受容体３９（ｇｐｒ３９）
WO2000035954A1 (fr) Recepteur couple de proteine g humaine
JP2008521419A (ja) Ｇタンパク質共役型受容体
JPH1175870A (ja) 新規なヒトｇ−タンパク質結合レセプター（ｈｃｅｐｔ０９）
EP1255779A2 (fr) Identification de modulateurs de l'activite gpr41 ou gpr42
WO2005121356A1 (fr) Nouveau procédé de recherche par criblage
JP4638354B2 (ja) Ｇ蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物
CA2404679C (fr) Recepteur couple aux proteines-g
JP2006290826A (ja) スクリーニング方法
EP2575860A1 (fr) Applications de diagnostic, de dépistage et thérapeutiques d'outils à base de la protéine ocab
KR20090111346A (ko) 이피에프 수용체 에세이, 화합물 및 치료학적 조성물
EP1484396B1 (fr) Molecules s'associant au domaine terminal c dans une cellule receptrice
EP3528831B1 (fr) Utilisation de polypeptides et d'acides nucléiques fkbp-l servant au traitement de l'obésité
JPWO2005093068A1 (ja) 新規タンパク質及びプロモーター
EP1945661B1 (fr) Récepteur gpr 146
WO2006118289A1 (fr) Procede pour l’identification d’un compose ayant un effet antidepresseur
JPWO2003080831A1 (ja) 核内受容体ＥＲＲγ３
TW201131168A (en) Methods and compositions for identifying modulators of G protein-coupled receptors
JP2002504493A (ja) Ｍｕｃｉｌａｇｅ、Ｇタンパク質共役型受容体

Legal Events

Date Code Title Description
A045 Written measure of dismissal of application

Free format text: JAPANESE INTERMEDIATE CODE: A043

Effective date: 20100126